RCT: Intramuscular tixagevimab–cilgavimab may benefit non-hospitalized unvaccinated adults with Covid-19.

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial – The Lancet Respiratory Medicine

Commentaries:

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID – News Medical

Expert reaction to results of the TACKLE Phase 3 trial of Evusheld (tixagevimab and cilgavimab) for treating early COVID-19 in outpatients – Science Media Centre

Commentary on Twitter

NEW—A single intramuscular tixagevimab–cilgavimab dose provided protection against progression to severe COVID-19 or death vs placebo in unvaccinated individuals

TACKLE trial from Prof Hugh Montgomery & colleagues https://t.co/M9LENFsA2C pic.twitter.com/Aon4wJsBOi

— The Lancet Respiratory Medicine (@LancetRespirMed) June 8, 2022